Eli Lilly's Retatrutide Achieves Significant Weight Loss in Clinical Trials
Eli Lilly’s obesity drug shows up to 30% weight loss in trial
Image: The Economic Times
Eli Lilly's experimental obesity drug, retatrutide, demonstrated up to 30% weight loss in a late-stage clinical trial, positioning it as a leading weight-loss treatment. In the Phase 3 TRIUMPH-1 study, participants lost an average of 31.9 kg over 80 weeks, with improvements in cardiometabolic health markers.
- 01In the Phase 3 TRIUMPH-1 study, participants on the highest 12 mg dose lost an average of 31.9 kg, or 28.3% of their body weight.
- 02Nearly 45% of participants on the 12 mg dose achieved at least 30% weight reduction, comparable to bariatric surgery outcomes.
- 03Participants with severe obesity in a two-year extension study lost an average of 38.5 kg, or 30.3%, at 104 weeks.
- 04At the lowest 4 mg dose, participants lost an average of 21.4 kg, or 19% of body weight, with lower discontinuation rates due to adverse events.
- 05Retatrutide improved cardiometabolic risk markers, including waist circumference and triglycerides, indicating enhanced health outcomes.
Advertisement
In-Article Ad
Eli Lilly's experimental obesity drug, retatrutide, has shown promising results in a pivotal late-stage clinical trial, known as the Phase 3 TRIUMPH-1 study. The drug, a once-weekly injectable triple hormone receptor agonist, targets GIP, GLP-1, and glucagon receptors, and helped participants lose an average of 31.9 kg, or 28.3% of their body weight over 80 weeks at the highest dose of 12 mg. Remarkably, nearly 45% of participants achieved a weight reduction of at least 30%, a benchmark typically associated with bariatric surgery outcomes. In a two-year extension study, participants with severe obesity continued to see significant weight loss, averaging 38.5 kg, or 30.3%, after 104 weeks. Even at the lower 4 mg dose, participants experienced an average weight loss of 21.4 kg, or 19%. Importantly, retatrutide also led to improvements in several cardiometabolic risk markers, including waist circumference and triglycerides. Ania Jastreboff, the lead investigator from the Yale Obesity Research Center, highlighted the drug's potential to transform obesity treatment and improve patients' health trajectories.
Advertisement
In-Article Ad
The success of retatrutide could provide a new treatment option for individuals struggling with obesity, potentially improving their overall health and reducing obesity-related health risks.
Advertisement
In-Article Ad
Reader Poll
Do you believe new obesity treatments like retatrutide can significantly impact public health?
Connecting to poll...
More about Eli Lilly
Read the original article
Visit the source for the complete story.